David M. Rodman is the new chief development strategy officer at ProQR Therapeutics, a leader in RNA therapies for cystic…
Articles by Daniela Semedo, PhD
Canon BioMedical has developed 21 Novallele genotyping assays that can detect changes within the cystic fibrosis transmembrane conductance regulator (CFTR) — the…
Vertex Pharmaceuticals is acquiring CTP-656, a potentiator treatment for the protein that is defective in cystic fibrosis, from Concert…
Researchers conducting a Phase 1 study for cystic fibrosis (CF) have dosed their first healthy volunteer with a combination of…
Researchers are developing a compact respiratory device that will allow children whose lungs have failed from cystic fibrosis (CF) or…
Online vlogs — the video equivalents of web journals or blogs — can be an important platform for patients and families living with…
The top 10 priorities for cystic fibrosis research — set by CF patients and specialists alike — range from learning…
Corbus Pharmaceuticals has completed its Phase 2 clinical trial  evaluating Resunab (JBT-101) for the treatment of adults with cystic…
A number of important discoveries, therapeutic developments, and events related to cystic fibrosis (CF) were reported daily by Cystic Fibrosis…
Galapagos NV recently reported positive topline results from SAPHIRA 1, a Phase 2 clinical trial assessing the company’s potentiator molecule,…